The U.S. Food and Drug Administration has approved a new first line treatment for adults with metastatic triple negative breast cancer who cannot receive immunotherapy, offering a much needed alternative to traditional chemotherapy for a group that has had few options. The drug, Datroway (datopotamab deruxtecan), is the first TROP2 directed antibody drug conjugate cleared for this specific patient population.
Approval followed Priority Review of the TROPION Breast02 Phase III trial, which enrolled 644 patients across five continents. The study found that Datroway improved median overall survival by 5.0 months compared to chemotherapy, with a hazard ratio of 0.79. Patients taking the drug also experienced a 43 percent reduction in the risk of disease progression or death, and the objective response rate was 64 percent versus 30 percent for chemotherapy. For the first time in this setting, the median overall survival reached two years.
Triple negative breast cancer accounts for about 15 percent of all breast cancer cases, or roughly 345,000 diagnoses globally each year. It is more common in younger and premenopausal women and disproportionately affects Black and Hispanic women. Approximately 70 percent of patients with metastatic disease are not candidates for PD 1/PD L1 inhibitor therapy, meaning chemotherapy was previously the only approved first line treatment. Datroway works by targeting the TROP2 protein, which is widely expressed in solid tumors including triple negative breast cancer and is linked to tumor progression and poor survival.
What This Means for Patients and Next Steps
The safety profile observed in the trial was consistent with earlier studies of Datroway in breast cancer. The application was reviewed under Project Orbis, a framework that allows concurrent review among international regulators. Reviews are ongoing in Australia, Canada, Singapore and Switzerland, with additional submissions underway in the European Union, China and Japan. Based on the trial results, Datroway has also been included in the NCCN Clinical Practice Guidelines as a Category 1 Preferred first line treatment option for this patient group.
With this approval, Datroway is now cleared for three indications in the United States, including two for breast cancer. Researchers continue to study its potential across tumor types, stages and treatment settings. For the many patients who have faced metastatic triple negative breast cancer with only chemotherapy available at the start of their treatment, this approval marks a meaningful shift toward more effective, targeted care.